NeuroPace Inc (NAS:NPCE)
$ 7.53 -0.07 (-0.92%) Market Cap: 216.62 Mil Enterprise Value: 232.78 Mil PE Ratio: 0 PB Ratio: 15.23 GF Score: 55/100

Neuropace Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 04:20PM GMT
Release Date Price: $4.1 (+2.50%)
Andrew Christopher Ranieri
Morgan Stanley, Research Division - Equity Analyst

All right, everyone. We can go ahead and get started. So welcome to another session at the Morgan Stanley Healthcare Conference. I'm Andrew Ranieri, one of the medical device analysts here. I'm delighted to have Michael Favet, CEO; and Rebecca Kuhn, CFO of NeuroPace. And before we just jump into it, I'd have to read our quick disclaimer. But for important disclosures, please see Morgan Stanley's research disclosure website morganstanley.com/researchdisclosures -- and if you have any questions, just reach out to your sales rep.

Questions & Answers

Andrew Christopher Ranieri
Morgan Stanley, Research Division - Equity Analyst

So with that, let's kind of kick it off. And Mike, maybe let's start on kind of the EMU volumes here. I mean, this has kind of been one of the ongoing debates and we've seen a lot of kind of fits and starts over Covid and maybe more recently in 2022 as we kind of moved into an endemic phase. So maybe just kind of give us an update on EMU volumes and if

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot